Fifth Third Wealth Advisors LLC Invests $448,000 in Insulet Corporation $PODD

Fifth Third Wealth Advisors LLC purchased a new position in Insulet Corporation (NASDAQ:PODD) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,426 shares of the medical instruments supplier’s stock, valued at approximately $448,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Inspire Investing LLC grew its holdings in shares of Insulet by 299.5% in the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock worth $1,082,000 after acquiring an additional 3,088 shares during the period. Goldman Sachs Group Inc. grew its holdings in Insulet by 1.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock valued at $152,130,000 after buying an additional 10,628 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Insulet by 55.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier’s stock valued at $1,376,000 after buying an additional 1,867 shares during the last quarter. Gradient Investments LLC acquired a new stake in Insulet during the 2nd quarter valued at $17,429,000. Finally, Vident Advisory LLC acquired a new stake in shares of Insulet during the first quarter worth $216,000.

Insulet Stock Down 1.8%

Shares of Insulet stock opened at $314.52 on Monday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $22.14 billion, a P/E ratio of 95.60, a P/E/G ratio of 2.61 and a beta of 1.40. Insulet Corporation has a fifty-two week low of $226.50 and a fifty-two week high of $353.50. The business has a 50-day moving average price of $323.75 and a 200 day moving average price of $300.64.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet’s quarterly revenue was up 32.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the topic of several research reports. The Goldman Sachs Group cut their target price on Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Oppenheimer boosted their price objective on Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research note on Monday, September 8th. Truist Financial assumed coverage on Insulet in a research note on Monday, June 16th. They set a “buy” rating and a $365.00 price objective on the stock. Morgan Stanley restated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Finally, Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $347.67.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.